特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EU5カ国におけるMA (メディカルアフェアーズ) 部門の評価:2型糖尿病経口薬

Medical Affairs Reputations: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

発行 FirstWord 商品コード 629542
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
詳細については [見積・お問合せ] ボタンよりお問い合わせ下さい。
EU5カ国におけるMA (メディカルアフェアーズ) 部門の評価:2型糖尿病経口薬 Medical Affairs Reputations: Type 2 Diabetes Mellitus [Orals] (EU5) 2018
出版日: 2018年02月01日 ページ情報: 英文
概要

当レポートでは、2型糖尿病の経口治療薬の主要9製品を取り扱う各社メディカルアフェアーズ (MA) チームについて、フランス、イタリア、ドイツ、スペイン、英国の糖尿病専門医150名を対象に調査を行った結果から、各社チームのパフォーマンスおよび満足度に対するスコアリングおよびランキング、医師によるサービス利用の動向、要望、改善箇所などの分析をまとめています。

対象の企業・ブランド

  • Forxiga (ダパグリフロジン:AstraZeneca)
  • Glyxambi (エンパグリフロジン/リナグリプチン:Eli Lilly/Boehringer Ingelheim)
  • Invokana (カナグリフロジン:Janssen Cilag)
  • Januvia (シタグリプチンリン:Merck Sharp & Dohme)
  • Jardiance (エンパグリフロジン:Eli Lilly/Boehringer Ingelheim)
  • Onglyza (サクサグリプチン:AstraZeneca)
  • Qtern (サクサグリプチン/ダパグリフロジン:AstraZeneca)
  • Trajenta (リナグリプチン:Eli Lilly/Boehringer Ingelheim)
  • Vipidia (アログリプチン:武田薬品工業)

調査・分析内容の例

  • 医師のニーズ
    • 医師によるMAチームの利用方法・頻度
    • もっとも重要と考えるサービス
    • 最適なコンタクトの頻度と経路
  • MAチームの提供する内容
    • 医師によるチームとのインタラクションの印象
    • 医師によるチームのパフォーマンス・満足度ランキング:12項目
    • 他のチームとの比較
  • 改善が必要な箇所、など

第1章 調査手法・サンプリング法・対象製品・エグゼクティブサマリー

第2章 MAチームとのインタラクションの現状

  • 過去6か月間の各製品のMAチームとのインタラクション
  • 各製品のMAチームとのコンタクトの頻度

第3章 MAチームパフォーマンスの競合的評価

  • 各製品のMAチームとのインタラクションの総合的な品質評価
  • 医師の医療行為におけるMAチームの重要度
  • エッジマップ分析:MAチームパフォーマンスの各種属性における競合的評価
  • MAチームとのインタラクションに対する医師の満足度の評価
  • ニーズギャップ分析:製品別

第4章 最適なコンタクトの頻度・経路と改善案

第5章 付録

目次

Compare 9 Type 2 Diabetes Mellitus medical affairs teams. See how your team stacks up to the market leader

In the EU5, several of the Type 2 Diabetes Mellitus medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 diabetologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: Type 2 Diabetes Mellitus (Orals) (EU5). Comparing 9 major Type 2 Diabetes Mellitus (Orals) treatments from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Janssen Cilag, Merck Sharp & Dohme, and Takeda, this detailed report reveals:

  • How diabetologists rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important.
  • What you can do to improve your medical affairs services.
  • How, and how often diabetologists want to meet with your team.

That's actionable information you can use to turn your team into one that doctors rely on.

Top Takeaways

  • Can the runaway leader at the top be chased down? Nearly 10 points separate the leading brand from second place in terms of overall quality of interactions. Is it really a race for second place or can brands make up with significant lead.
  • Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions.
  • Huge variations in activity. In the past six months, only 1 of the 9 teams interacted with more than 70% of doctors surveyed, and the least active teams saw no more than 29% of them.
  • Doctors want to see teams in-person and not too often. The report reveals how, and how frequently your team should engage.
  • Digital interaction still some way off becoming the norm. For the most part, doctors want personal interactions, not emails or phone calls. Does this align with your strategy?

Insight into Medical Affairs Teams for These 9 Type 2 Diabetes Mellitus Treatments

  • Forxiga (dapagliflozin; AstraZeneca)
  • Glyxambi (empagliflozin/linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Invokana (canagliflozin; Janssen Cilag)
  • Januvia (sitagliptin; Merck Sharp & Dohme)
  • Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim)
  • Onglyza (saxagliptin; AstraZeneca)
  • Qtern (saxagliptin/dapagliflozin; AstraZeneca)
  • Trajenta (linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Vipidia (alogliptin; Takeda)

A Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 9 medical affairs teams-answering important questions like:

What do physicians need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 diabetologists from the EU5 (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with Type 2 Diabetes Mellitus in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the past 6 months.

We conducted the survey between February 6-15, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

1. Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary

2. Current Status of Interactions with Different Medical Affairs Teams

  • 2.1. Interactions in the past 6 months with Medical Affairs teams for each product
  • 2.2. Current frequency of interactions with medical affair teams for each product

3. Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes

  • 3.1. Evaluation of overall quality of interactions with Medical Affairs teams for each product
  • 3.2. Attribute importance of Medical Affairs teams roles to physicians' practice
  • 3.3. EdgeMap analysis - Competitive evaluation on Medical Affairs teams performance on attributes
  • 3.4. Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
  • 3.5. Need-Gap analysis by product

4. Preferred Interaction Media, Frequency, and Suggestions for Improvement

  • 4.1. Preferred interaction media and frequency, and suggestions for improvement

5. Appendix